Intravitreal Bevacizumab (Avastin) for Choroidal Neovascularization in Angioid Streaks: A Case Series
2008; Karger Publishers; Volume: 223; Issue: 1 Linguagem: Inglês
10.1159/000161879
ISSN1423-0267
AutoresMaria Carla Donati, Gianni Virgili, Alessandro Bini, Fabrizio Giansanti, Emilio Rapizzi, Giovanni Giacomelli, Ugo Menchini,
Tópico(s)Biomedical Research and Pathophysiology
Resumo<i>Background:</i> Intravitreal (IV) bevacizumab (Avastin®, Roche), initially used for the off-label treatment of neovascular age-related macular degeneration (AMD), has extended itself to treat various ocular pathologies such as choroidal neovascularization not associated to AMD. <i>Methods:</i> IV bevacizumab 1,25 mg (Avastin) was used in the treatment of choroidal neovascularization (CNV) in 6 eyes of 5 patients with angioid streaks. All cases had a history of photodynamic treatment (PDT) or laser treatment and all showed progressive worsening despite the use of these therapies. <i>Results:</i> After injection patients were followed up at nearly 2-month intervals. IV Avastin was repeated in case of recurrence. Three eyes were treated combining PDT and IV Avastin. Cases were followed up for 7–14 months. All patients needed more IV injections. Five out of 6 eyes showed an improvement of BCVA and a slight reduction of leakage and size with FA. <i>Conclusion:</i> This small series suggests that IV Avastin might be useful in the treatment of CNV due to AS.
Referência(s)